Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.52 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27692438 | 0.88 | HSD11B1 (0.62) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL27405 | 0.88 | MAPK1 (0.78) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL13505849 | 0.87 | MAPK1 (0.58) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL2397695 | 0.87 | MAPK1 (0.58) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL1074233 | 0.87 | MAPK1 (0.58) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL6052319 | 0.87 | MAPK1 (0.58) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL1420155 | 0.87 | KMT2A (0.61) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL15168308 | 0.85 | RAB9A (0.56) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL6319617 | 0.85 | MAPK1 (0.59) | MAPK1RAB9ANPC1SLC9A1SLC9A2 | |
| SCHEMBL15168370 | 0.84 | RAB9A (0.64) | MAPK1RAB9ANPC1SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2837627-B1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2837627-A1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2657230-A1 | AMIDE DERIVATIVE AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | IL2, IL4, IL5 | MAPK1 764/4885RAB9A 1528/4885NPC1 1134/4885 |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | MYLK, ROCK1, ROCK2 | MAPK1 183/4885RAB9A 464/4885NPC1 4344/4885 |
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | IL5, IL2, IL4 | MAPK1 291/4885RAB9A 1758/4885NPC1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.